Merck KGaA (MRK) Given a €98.00 Price Target by Morgan Stanley Analysts

Morgan Stanley set a €98.00 ($116.67) price objective on Merck KGaA (FRA:MRK) in a report issued on Friday morning. The firm currently has a neutral rating on the healthcare company’s stock.

A number of other equities research analysts have also recently weighed in on the company. UBS set a €120.00 ($142.86) price target on Merck KGaA and gave the company a buy rating in a report on Monday, October 23rd. equinet set a €112.00 ($133.33) price target on Merck KGaA and gave the company a buy rating in a report on Thursday, August 31st. Societe Generale set a €103.00 ($122.62) price target on Merck KGaA and gave the company a neutral rating in a report on Tuesday, September 5th. Goldman Sachs Group set a €105.00 ($125.00) price target on Merck KGaA and gave the company a neutral rating in a report on Wednesday, September 6th. Finally, Independent Research set a €105.00 ($125.00) price target on Merck KGaA and gave the company a neutral rating in a report on Monday, August 28th. Eleven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of €108.52 ($129.20).

Merck KGaA (FRA:MRK) opened at €89.82 ($106.93) on Friday. Merck KGaA has a 52 week low of €87.99 ($104.75) and a 52 week high of €115.00 ($136.90).

ILLEGAL ACTIVITY NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/12/05/merck-kgaa-mrk-given-a-98-00-price-target-by-morgan-stanley-analysts.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

What are top analysts saying about Merck KGaA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck KGaA and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit